Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
- Study ID
- NCT01849341
- Phase
- PHASE4
- Status
- Completed
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast alternated days — DRUG500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
- Roflumilast 500 mcg per day — DRUG
Study Details
It is a phase IV clinical trial: longitudinal, prospective, evaluator-blind, randomized into 2 groups of patients with chronic obstructive pulmonary disease (COPD). The intervention group was based on the administration of roflumilast 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks (phasing). In the control group assigned to undertake the treatment according to the standard dosage (roflumilast 500μg od). The patient monitoring will be done by one of the sub-investigators fully independent team that started the medication keeping the pattern masking by single blind, and since it aims to assess the frequency of adverse events (AEs) in both groups were collected systematically different AEs and their characteristics at 15 days (V1), and from that moment a month (V2) and 2 months (V3). Likewise, other data collected (functional demographic, comorbidities, home treatment, anxiety and depression and quality of life). The purpose of this study is to assess whether the administration of roflumilast by a gradual pattern varies the incidence of discontinuations due to adverse events when compared with the usual dosage.
Key Dates
- Start date
- Jul 31, 2012
- Status verified
- Jul 2015
- Primary completion
- Dec 31, 2013
- Completion
- Jul 31, 2014
Study Design
- Enrollment
- 105 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
Arms
- Experimental: Roflumilast alternated daysIntervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
- Active Comparator: Roflumilast 500 mcg per dayRoflumilast 500μg standard dosage
Primary Outcome Measure
Difference of Adverse Events [ Time Frame: 2 weeks ]
Related Studies
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesRecruiting · Weill Medical College of Cornell University · New York, New York
- Multi-Center Clean Air Randomized Controlled Trial in COPDPHASE3 · Recruiting · JHSPH Center for Clinical Trials · Birmingham, Alabama
- Quest to Analyze One Thousand Humans MeditatingEnrolling By Invitation · Tobias Moeller-Bertram · Palm Desert, California
- Effectiveness of the WearME System for COPD Severity and Respiratory FunctionRecruiting · LASARRUS Clinic and Research Center · Baltimore, Maryland